Association between toll-like receptor expression and human papillomavirus type 16 persistence

International Journal of Cancer

Volumn 128, Issue 4, 2011, Pages 879-886

  Daud, Ibrahim I ^a,b,c   Scott, Mark E ^d   Ma, Yifei ^d   Shiboski, Stephen ^d   Farhat, Sepideh ^d   Moscicki, Anna Barbara ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Kenya)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

human papillomavirus; persistence; toll like receptors

Indexed keywords

ALPHA2 INTERFERON; MESSENGER RNA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ADOLESCENT; ADULT; ARTICLE; CERVICAL LAVAGE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN TISSUE; IMMUNOASSAY; INCIDENCE; INNATE IMMUNITY; LAVAGE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; QUANTITATIVE STUDY; RANK SUM TEST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; VIRAL CLEARANCE; WART VIRUS;

ADOLESCENT; ADULT; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNITY, INNATE; INTERFERON-ALPHA; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; RESPIRATORY TRACT NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TOLL-LIKE RECEPTORS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 78650542756     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25400     Document Type: Article

References (43)

1. Muñoz N, Bosch FX, De Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ,. Epidemiological classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27. (Pubitemid 36159887)
2. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV,. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) study group. J Natl Cancer Inst 1995; 87: 796-802.
3. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, Darragh TM, Brescia R, Kanowitz S, Miller SB, Stone J, Hanson E, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 1998; 132: 277-84.
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N,. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
5. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 2005; 337: 76-84.
6. Nakagawa M, Stites D, Patel S, Scott M, Hills N, Palefsky J, Moscicki AB,. Persistence of human papillomavirus 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigen. J Infect Dis 2000; 182: 595-8.
7. Scott M, Stites DP, Moscicki AB,. Th1 cytokine patterns in cervical human papillomavirus infection. Clin Diagn Lab Immunol 1999; 6: 751-5.
8. Stanley M,. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008; 109: S15-S21.
9. Woodworth CD,. HPV innate immunity. Front Biosci 2002; 7: d2058-d2071.
10. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA,. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181: 1911-19.
11. Frazer IH,. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 2009; 384: 410-14.
12. Wang X, Moscicki AB, Tsang L, Brockman A, Nakagawa M,. Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable. Clin Vaccine Immunol 2008; 15: 937-45.
13. Farhat S, Nakagawa M, Moscicki AB,. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzyme-linked immunospot in women with cleared or persistent human papillomavirus infection. Int J Gynecol Cancer 2009; 19: 508-12.
14. Stanley M,. Immune responses to human papillomavirus. Vaccine 2006; 24 (Suppl 1): S16-S22.
15. Takeda K, Akira S,. Toll-like receptors in innate immunity. Int Immunol 2005; 17: 1-14.
16. Brugnolo F, Sampognaro S, Liotta F, Cosmi L, Annunziato F, Manuelli C, Campi P, Maggi E, Romagnani S, Parronchi P,. The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells. J Allergy Clin Immunol 2003; 111: 380-8.
17. Kaisho T, Akira S,. Pleiotropic function of Toll-like receptors. Microbes Infect 2004; 6: 1388-94.
18. Klinman DM,. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004; 4: 249-58.
19. Barton GM,. Viral recognition by Toll-like receptors. Semin Immunol 2007; 19: 33-40.
20. Hasan UA, Bates E, Takeshita F, Biliato A, Accardi R, Bouvard V, Mansour M, Vincent I, Gissmann L, Iftner T, Sideri M, Stubenrauch F, et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 2007; 178: 3186-97.
21. Yang R, Murillo FM, Delannoy MJ, Blosser RL, Yutzy WH, Uematsu S, Takeda K, Akira S, Viscidi RP, Roden RBS,. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88. J Immunol 2005; 174: 7912-19.
22. Scott ME, Ma Y, Farhat S, Shiboski S, Moscicki AB,. Covariates of cervical cytokine mRNA expression by real-time PCR in adolescents and young women: effects of Chlamydia trachomatis infection, hormonal contraception, and smoking. J Clin Immunol 2006; 26: 222-32.
23. Lieberman JA, Moscicki AB, Sumerel JL, Ma Y, Scott ME,. Determination of cytokine protein levels in cervical mucus samples from young women by a multiplex immunoassay method and assessment of correlates. Clin Vaccine Immunol 2008; 15: 49-54.
24. Daud II, Scott ME,. Validation of reference genes in cervical cell samples from human papillomavirus-infected and -uninfected women for quantitative reverse transcription-PCR assays. Clin Vaccine Immunol 2008; 15: 1369-73.
25. Cui W, Taub DD, Gardner K,. qPrimerDepot: a primer database for quantitative real time PCR. Nucleic Acids Res 2007; 35: D805-D809.
26. Pattyn F, Robbrecht P, De Paepe A, Speleman F, Vandesompele J,. RTPrimerDB: the real-time PCR primer and probe database, major update 2006. Nucleic Acids Res 2006; 34: D684-D688.
27. Rebbapragada A, Wachihi C, Pettengell C, Sunderji S, Huibner S, Jaoko W, Ball B, Fowke K, Mazzulli T, Plummer FA, Kaul R,. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS 2007; 21: 589-98.
28. Bookout AL, Cummins CL, Mangelsdorf DJ, Pesola JM, Kramer MF,. High-throughput real-time quantitative reverse transcription PCR. Curr Protoc Mol Biol 2006;Chapter 15:Unit 15.8.
29. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F,. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: research0034-1-0034-12.
30. Hochberg YA,. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75: 800-2.
31. Warger T, Osterloh P, Rechtsteiner G, Fassbender M, Heib V, Schmid B, Schmitt E, Schild H, Radsak MP,. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 2006; 108: 544-50.
32. Whitmore MM, DeVeer MJ, Edling A, Oates RK, Simons B, Lindner D, Williams BRG,. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res 2004; 64: 5850-60.
33. Bieback K, Lien E, Klagge IM, Avota E, Schneider-Schaulies J, Duprex WP, Wagner H, Kirschning CJ, Ter Meulen V, Schneider-Schaulies S,. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. J Virol 2002; 76: 8729-36.
34. Compton T, Kurt-Jones EA, Boehme KW, Belko J, Latz E, Golenbock DT, Finberg RW,. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol 2003; 77: 4588-96.
35. Chang S, Dolganiuc A, Szabo G,. Toll-like receptors 1 and 6 are involved in TLR2-mediated macrophage activation by hepatitis C virus core and NS3 proteins. J Leukoc Biol 2007; 82: 479-87.
36. Kurt-Jones EA, Chan M, Zhou S, Wang J, Reed G, Bronson R, Arnold MM, Knipe DM, Finberg RW,. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci USA 2004; 101: 1315-20.
37. Szomolanyi-Tsuda E, Liang X, Welsh RM, Kurt-Jones EA, Finberg RW,. Role for TLR2 in NK cell-mediated control of murine cytomegalovirus in vivo. J Virol 2006; 80: 4286-91.
38. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW,. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1: 398-401.
39. Jimenez-Flores R, Mendez-Cruz R, Ojeda-Ortiz J, Muñoz-Molina R, Balderas-Carrillo O, de la Luz Diaz-Soberanes M, Lebecque S, Saeland S, Daneri-Navarro A, Garcia-Carranca A, Ullrich SE, Flores-Romo L,. High-risk human papilloma virus infection decreases the frequency of dendritic Langerhans' cells in the human female genital tract. Immunology 2006; 117: 220-8.
40. Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL,. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006; 24: S26-S34.
41. Vitali B, Pugliese C, Biagi E, Candela M, Turroni S, Bellen G, Donders GG, Brigidi P,. Dynamics of vaginal bacterial communities in women developing bacterial vaginosis, candidiasis, or no infection, analyzed by PCR-denaturing gradient gel electrophoresis and real-time PCR. Appl Environ Microbiol 2007; 73: 5731-41.
42. Stanley MA,. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002; 27: 571-7.
43. van Poelgeest MIE, van Seters M, van Beurden M, Kwappenberg KMC, Heijmans-Antonissen C, Drijfhout JW, Melief CJM, Kenter GG, Helmerhorst TJM, Offringa R, van der Burg SH,. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin Cancer Res 2005; 11: 5273-80.